High frequency of fluoroquinolone- and macrolide-resistant streptococci among clinically isolated group b streptococci with reduced penicillin susceptibility

Journal of Antimicrobial Chemotherapy

Volumn 68, Issue 3, 2013, Pages 539-542

  Kimura, Kouji ^a,b   Nagano, Noriyuki ^c   Nagano, Yukiko ^b   Suzuki, Satowa ^b   Wachino, Jun Ichi ^a,b   Shibayama, Keigo ^b   Arakawa, Yoshichika ^a,b  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL INSTITUTE OF INFECTIOUS DISEASES   (Japan)

^c Funabashi Municipal Medical Center   (Japan)

Author keywords

Erythromycin; GBS; Levofloxacin; PRGBS

Indexed keywords

ERYTHROMYCIN; LEVOFLOXACIN; MACROLIDE; PENICILLIN G; QUINOLONE DERIVATIVE;

AGAR DILUTION; AMINO ACID SUBSTITUTION; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GENE; BACTERIUM ISOLATE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS AGALACTIAE;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, BACTERIAL; ELECTROPHORESIS, GEL, PULSED-FIELD; FLUOROQUINOLONES; HUMANS; JAPAN; MACROLIDES; MICROBIAL SENSITIVITY TESTS; MOLECULAR TYPING; PENICILLINS; PREVALENCE; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE;

EID: 84873580629     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks423     Document Type: Article

References (20)

1. Baker CJ. Group B streptococcal infections. In: Stevens DL, Kaplan EL. Streptococcal Infections. Clinical Aspects, Microbiology, and Molecular Pathogenesis. Oxford: Oxford University Press, 2000; 222-37.
2. Schuchat A. Group B streptococcus. Lancet 1999; 353: 51-6.
3. Schuchat A. Epidemiology of Group B streptococcal disease in the United States: shifting paradigms. Clin Microbiol Rev 1998; 11: 497-513.
4. Farley MM, Harvey RC, Stull T et al. A population-based assessment of invasive disease due to group B streptococcus in nonpregnant adults. N Engl J Med 1993; 328: 1807-11.
5. Jackson LA, Hilsdon R, Farley MM et al. Risk factors for group B streptococcal disease in adults. Ann Intern Med 1995; 123: 415-20.
6. Schrag S, Gorwitz R, Fultz-Butts K et al. Prevention of perinatal group B streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 2002; 51: 1-22.
7. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Nineteenth Informational Supplement M100-S19. CLSI, Wayne, PA, USA, 2009.
8. Kimura K, Suzuki S, Wachino J et al. First molecular characterization of group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008; 52: 2890-7.
9. Kimura K, Nagano N, Nagano Y et al. Predominance of sequence type 1 group with serotype VI among group B streptococci with reduced penicillin susceptibility identified in Japan. J Antimicrob Chemother 2011; 66: 2460-4.
10. Nagano N, Nagano Y, Kimura K et al. Genetic heterogeneity in pbp genes among clinically isolated group B streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 2008; 52: 4258-67.
11. Nagano N, Kimura K, Nagano Y et al. Molecular characterization of group B streptococci with reduced penicillin susceptibility recurrently isolated from sacral decubitus ulcer. J Antimicrob Chemother 2009; 64: 1326-8.
12. Murayama SY, Seki C, Sakata H et al. Capsular type and antibiotic resistance in Streptococcus agalactiae isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob Agents Chemother 2009; 53: 2650-3.
13. Dahesh S, Hensler ME, Van Sorge NM et al. Point mutation in the group B streptococcal pbp2x gene conferring decreased susceptibility to b-lactam antibiotics. Antimicrob Agents Chemother 2008; 52: 2915-8.
14. Gaudreau C, Lecours R, Ismaïl J et al. Prosthetic hip joint infection with a Streptococcus agalactiae isolate not susceptible to penicillin G and ceftriaxone. J Antimicrob Chemother 2009; 65: 594-5.
15. Longtin J, Vermeiren C, Shahinas D et al. Novel mutations in a patient isolate of Streptococcus agalactiae with reduced penicillin susceptibility emerging after long-term oral suppressive therapy. Antimicrob Agents Chemother 2011; 55: 2983-5.
16. EUCAST. Breakpoint Tables for Interpretation of MICs and Zone Diameters, Version 1.3. EUCAST, Växjö, Sweden, 2011; 25-9.
17. Kimura K, Wachino J, Kurokawa H et al. Practical disk diffusion test for detecting group B streptococcus with reduced penicillin susceptibility. J Clin Microbiol 2009; 47: 4154-7.
18. Marimón JM, Valiente A, Ercibengoa M et al. Erythromycin resistance and genetic elements carrying macrolide efflux genes in Streptococcus agalactiae. Antimicrob Agents Chemother 2005; 49: 5069-74.
19. Gygax SE, Schuyler JA, Kimmel LE et al. Erythromycin and clindamycin resistance in group B streptococcal clinical isolates. Antimicrob Agents Chemother 2006; 50: 1875-7.
20. Nagano N, Nagano Y, Toyama M et al. Nosocomial spread of multidrug-resistant group B streptococci with reduced penicillin susceptibility belonging to clonal complex 1. J Antimicrob Chemother 2012; 67: 849-56.